Flowtech Fluidpower a strong performance despite a pandemic (Analyst Interview)

Flowtech Fluidpower plc (LON:FLO) is the topic of conversation when Andy Hanson, Research Analyst at Zeus Capital discusses interim results. Andy talks us through the key highlights, how the company performed during the pandemic, the outlook and the company and an investment opportunity.

Founded as Flowtech in 1983, the Flowtech Fluidpower Group is the UK’s leading specialist supplier of technical fluid power products and services. The business joined AIM in 2014 (AIM: Symbol FLO). Today, the Group has two distinct divisions: Components. Supply of hydraulic and pneumatic consumables, predominantly through distribution for urgent maintenance and repair operations across all industry sectors. Additionally, support a broad range of original equipment manufacturers (OEMs) supplying off-the-shelf and tailored components and assemblies. Services. Bespoke design, manufacturing, commissioning, installation, and servicing of systems to manufacturers of specialised industrial and mobile hydraulic original equipment manufacturers (OEMs) and additionally a wide range of industrial end users. Both Group’s divisions have overlapping product sets, allowing procurement synergies to be maximised.

The divisions are supported by a centralised back office team based in Wilmslow, Cheshire, UK and a procurement and quality control team in Shanghai, China. In total, the business employs c.600 people.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Flowtech Fluidpower

    More articles like this

    Guild Esports sign two-year gaming chair sponsorship with Razer

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global teams organisation and lifestyle brand, has welcome Razer as the Company’s Official Gaming Chair Partner with the signing of a two-year global sponsorship deal. The total contract value, which

    Redde Northgate trading ahead of expectations

    Redde Northgate plc (LON:REDD), the leading integrated mobility solutions platform providing services across the vehicle lifecycle, has announced a trading update for the year ended 30 April 2022, ahead of its results for the year scheduled

    Inchcape

    Inchcape update on Russian operations

    Inchcape plc (LON:INCH) is deeply saddened by the ongoing conflict in Ukraine and the enormous humanitarian impact on all those affected. We share the hopes of the world for a peaceful resolution. In light of the current

    STRIX GROUP PLC ORD 1P

    Strix Group to conduct investor presentation on 31st March 2022

    Strix Group plc (LON:KETL), the global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components will be conducting an investor presentation covering their Full Year results to the period

    City of London Investment Group plc

    City of London Investment Group Barry Olliff increases holding

    City of London Investment Group plc (LON:CLIG), a leading specialist asset management group offering a range of institutional and retail products investing primarily in closed-end funds, stated that it has been notified that Stable View III LP,

    CentralNic

    CentralNic Group continue to beat expectations (Analyst Interview)

    CentralNic Group Plc (LON:CNIC) is the topic of conversation when Bob Liao Director and Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Bob provides us with an overview of VGL, explains how the acquisition fits in with CentalNic’s business,

    Guild Esports wins fifth major trophy

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global team organisation and lifestyle brand, has announced that it has won its fifth major trophy after its Fortnite pro-player, Henrik Mclean (‘Hen’), achieved first place in the prestigious Fortnite

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous